Zoe Quandt, MD

Endocrine Clinical Fellow (MD MS)

Co-Mentor (Mark Anderson)

Diabetes Center

Email:

Zoe completed her MD at UCSF and her MS in Health and Medical Sciences at UC Berkeley. She completed her residency training in Internal Medicine at Stanford Hospital and Clinics prior to returning to UCSF for her Endocrinology and Diabetes for fellowship. Her research focus is in endocrine immune related adverse events following cancer immunotherapy. She is a recipient of the American Diabetes Association Postdoctoral Fellowship.

Zoe enjoys outdoor adventures and trying out hole-in-the wall restaurants

Publications:

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.

Nature communications

Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E

Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score.

Cancer research

Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Princess Margaret Lung Group, Matthew A. Gubens, Christine M. Lovly, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.

NPJ breast cancer

Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.

Frontiers in endocrinology

Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.

The oncologist

Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt Z

Genetic prediction of colitis in non-small cell lung cancer patients on immune checkpoint inhibitor therapy.

medRxiv : the preprint server for health sciences

Middha P, Thummalapalli R, Betti MJ, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?

Frontiers in endocrinology

Gomes-Lima CJ, Zhou W, Quandt Z

Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having.

Cancer

Sharon E, Othus M, Quandt ZE

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Journal of Clinical Oncology

Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo

The cognitive load of inpatient consults involving immune-related adverse events.

Journal of Clinical Oncology

Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt

Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.

Journal of the Endocrine Society

Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U

Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.

Nature biotechnology

Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T

Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.

Diabetes

Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL

Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq.

eLife

Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Proekt I, Yu D, Mandel-Brehm C, Wang CY, Miao B, Sowa G, Zorn K, Chan AY, Tagi VM, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kämpe O, Dobbs K, Delmonte OM, Bacchetta R, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Journal of Clinical Oncology

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.

JCI insight

Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC

189-OR: Immune-Profiling of Pancreatic Tissue Affected by Immune Checkpoint Inhibitor–Induced Diabetes (CPI-D).

Diabetes

ZOE QUANDT, ARABELLA YOUNG, GRAHAM BARLOW, SHEN DONG, JENNIFER SMITH, IRINA KUSMARTSEVA, TODD M. BRUSKO, STEWART COOPER, MARK S. ANDERSON

Evaluating survival following severe immune-related adverse events requiring hospitalization.

Journal of Clinical Oncology

Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield

Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.

Journal of Clinical Oncology

Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon

Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq.

bioRxiv : the preprint server for biology

Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Mandel-Brehm C, Miao B, Sowa G, Zorn K, Chan AY, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kampe O, Dobbs K, Delmonte OM, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL

Patient-Centered Diabetes Care of Cancer Patients.

Current diabetes reports

Kotwal A, Cheung YM, Cromwell G, Drincic A, Leblebjian H, Quandt Z, Rushakoff RJ, McDonnell ME

Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E

Case 20: Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes.

Zoe Quandt, Paras Mehta, Katy Tsai, Victoria Hsiao, Robert Rushakoff

Case 21: Checkpoint Inhibitor–Induced Diabetes.

Paras Mehta, Zoe Quandt, Robert Rushakoff

Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.

Annual review of medicine

Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS

Breaking ß Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus.

Journal of the Endocrine Society

Quandt Z, Coupe C, Anderson M, Uihlein A, Young A

Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq.

eLife

Vazquez SE, Ferré EM, Scheel DW, Sunshine S, Miao B, Mandel-Brehm C, Quandt Z, Chan AY, Cheng M, German M, Lionakis M, DeRisi JL, Anderson MS

SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events.

Journal of the Endocrine Society

Zoe Quandt, Laura Trupin, Michael Evans, Gabriela Schmajuk, Mark Stuart Anderson, Jeff A Bluestone, Yazdany Jinoos

SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus.

Journal of the Endocrine Society

Zoe Quandt, Katy K Tsai, Victoria C Hsiao

SUN-298 Spectrum of Imaging in Immune Checkpoint Inhibitor Induced Hypophysitis.

Journal of the Endocrine Society

Zoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, Catherine Coupe, J Blake Tyrrell, Jeffery A Bluestone, Mark Stuart Anderson, Umesh Masharani

Immune Checkpoint Inhibitor Diabetes Mellitus: A Novel Form of Autoimmune Diabetes.

Clinical and experimental immunology

Quandt Z, Young A, Anderson M

Chapter 19 Thyroid Disorders During Pregnancy, Postpartum, and Lactation.

Zoe E. Quandt, Kirsten E. Salmeen, Ingrid J. Block-Kurbisch

Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma.

The Journal of clinical investigation

Moore PC, Cortez JT, Chamberlain CE, Alba D, Berger AC, Quandt Z, Chan A, Cheng MH, Bautista JL, Peng J, German MS, Anderson M, Oakes SA

Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.

The lancet. Diabetes & endocrinology

Perdigoto AL, Quandt Z, Anderson M, Herold KC

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.

Cancer immunology research

Young A, Quandt Z, Bluestone JA

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Diabetes

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Search form

You are here

Zoe Quandt, MD